Shamburg News · 8-K filed Nov 9, 2026, 8:35 AM EST

Aptevo Therapeutics Presents Preclinical Multispecific Data at SITC 2026

APVO · Aptevo Therapeutics Inc.

  • Other event
  • Materiality: low

On November 7, 2026, Aptevo Therapeutics Inc. presented new preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer 2026 Annual Meeting. The company reported that APVO451 and APVO452 showed tumor-cell killing and T-cell activation under immunosuppressive conditions, and that APVO711 combined CD40 activation with PD-L1 blockade. Aptevo announced the results in a press release dated November 9, 2026, filed as Exhibit 99.1.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001193125-26-452737.

Written from the filing by Shamburg Markets. Figures are as reported by the company.